Compound ID | 135
Synonym(s): Dalvance
Class: Glycopeptide
| Agent Type: | Semisynthetic; Direct acting; |
| Spectrum of activity: | Gram-positive |
| Mechanism of action: | Cell wall synthesis inhibitor |
| Target Pathogen: | Active against Gram-positives causing acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia |
| Description: | Semisynthetic derivative of teicoplanin; Dalbavancin: Phase I single and multiple-dose placebo controlled intravenous safety, pharmacokinetic study in healthy volunteers. 41st ICAAC By: Leighton, A.; Mrosczcak, E.; White, R.; et al. |
| Institute where first reported: | Actavis (formerly Durata Therapeutics), UK |
| Year first mentioned: | 2001 |
| Highest development stage: | Approved by FDA in 2014 |
| Development status: | Approved |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/16134627 |
| Guide to Pharmacology: | dalbavancin |
| Citations: |
|